Literature DB >> 1102508

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

C Vézina, A Kudelski, S N Sehgal.   

Abstract

A streptomycete was isolated from an Easter Island soil sample and found to inhibit Candida albicans, Microsporum gypseum and Trichophyton granulosum. The antibiotic-producing microorganism was characterized and identified as Streptomyces hygroscopicus. The antifungal principle was extracted with organic solvent from the mycelium, isolated in crystalline form and named rapamycin. Rapamycin is mainly active against Candida albicans; minimum inhibitory concentration against ten strains ranged from 0.02 to 0.2 mug/ml. Its apparent activity against Microsporum gypseum and Trichophyton granulosum is lower because of its instability in culture media on prolonged incubation required by these fungi. No activity was observed against gram-positive and gram-negative bacteria. Acute toxicity in mice is low.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1102508     DOI: 10.7164/antibiotics.28.721

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  378 in total

Review 1.  Advances in the development of immunosuppressive agents in organ transplantation.

Authors:  T Ochiai; K Isono
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

Review 2.  The target of rapamycin (TOR) proteins.

Authors:  B Raught; A C Gingras; N Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

3.  Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study.

Authors:  Ashok S Thakkar; Atul D Abhyankar; Sameer I Dani; Darshan N Banker; Parvinder I Singh; Sanjay A Parmar; Anita A Mehta
Journal:  Indian Heart J       Date:  2012 May-Jun

4.  Mds3 regulates morphogenesis in Candida albicans through the TOR pathway.

Authors:  Lucia F Zacchi; Jonatan Gomez-Raja; Dana A Davis
Journal:  Mol Cell Biol       Date:  2010-05-10       Impact factor: 4.272

5.  Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma.

Authors:  Murali Janakiram; Venu K Thirukonda; Matthew Sullivan; Adam M Petrich
Journal:  Curr Treat Options Oncol       Date:  2012-02-02

Review 6.  Constructing molecular complexity and diversity: total synthesis of natural products of biological and medicinal importance.

Authors:  K C Nicolaou; Christopher R H Hale; Christian Nilewski; Heraklidia A Ioannidou
Journal:  Chem Soc Rev       Date:  2012-06-28       Impact factor: 54.564

7.  Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist.

Authors:  Ran Zhu; Ashley H Snyder; Yugesh Kharel; Lisa Schaffter; Qin Sun; Perry C Kennedy; Kevin R Lynch; Timothy L Macdonald
Journal:  J Med Chem       Date:  2007-11-10       Impact factor: 7.446

Review 8.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

10.  Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.

Authors:  Zhi-Wei Lai; Ryan Kelly; Thomas Winans; Ivan Marchena; Ashwini Shadakshari; Julie Yu; Maha Dawood; Ricardo Garcia; Hajra Tily; Lisa Francis; Stephen V Faraone; Paul E Phillips; Andras Perl
Journal:  Lancet       Date:  2018-03-15       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.